Clearside Biomedical, Inc. Stock

Equities

CLSD

US1850631045

Biotechnology & Medical Research

Delayed Nasdaq 12:55:30 2024-04-16 pm EDT 5-day change 1st Jan Change
1.2 USD -6.98% Intraday chart for Clearside Biomedical, Inc. -6.98% +2.56%
Sales 2024 * 2.74M Sales 2025 * 7.36M Capitalization 96.39M
Net income 2024 * -39M Net income 2025 * -43M EV / Sales 2024 * 27.4 x
Net cash position 2024 * 21.26M Net Debt 2025 * 12.33M EV / Sales 2025 * 14.8 x
P/E ratio 2024 *
-2.45 x
P/E ratio 2025 *
-2.22 x
Employees 30
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.84%
More Fundamentals * Assessed data
Dynamic Chart
Clearside Biomedical Names Victor Chong Chief Medical Officer MT
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer CI
Wedbush Trims Clearside Biomedical's PT to $4 From $5 After Increased Share Count, Model Adjustments; Maintains Outperform Rating MT
Clearside Biomedical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Clearside Biomedical, Inc., Q4 2023 Earnings Call, Mar 12, 2024
Clearside Biomedical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Clearside Biomedical Shares Decline After Stock Sale by CEO, CFO MT
Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD CI
Transcript : Clearside Biomedical, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Clearside Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
BioCryst Pharmaceuticals, Clearside Biomedical Enter Drug Development Collaboration MT
Biocryst Pharmaceuticals, Inc. and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary Scs Microinjector CI
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting CI
Clearside Biomedical, Inc.(NasdaqGM:CLSD) dropped from S&P Global BMI Index CI
Transcript : Clearside Biomedical, Inc., Q2 2023 Earnings Call, Aug 14, 2023
More news
1 day+3.20%
Current month-15.69%
1 month-24.56%
3 months-11.03%
6 months+49.83%
Current year+10.26%
More quotes
1 week
1.21
Extreme 1.21
1.34
1 month
1.20
Extreme 1.2
1.80
Current year
1.10
Extreme 1.1
2.12
1 year
0.65
Extreme 0.6501
2.12
3 years
0.65
Extreme 0.6501
7.73
5 years
0.56
Extreme 0.56
7.73
10 years
0.56
Extreme 0.56
25.08
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 17-08-07
Director of Finance/CFO 59 11-12-31
Chief Tech/Sci/R&D Officer - 22-06-13
Members of the board TitleAgeSince
Chief Executive Officer 72 17-08-07
Director/Board Member 64 18-09-25
Director/Board Member 66 11-12-31
More insiders
Date Price Change Volume
24-04-16 1.2 -6.98% 226 402
24-04-15 1.29 +3.20% 184,316
24-04-12 1.25 -3.85% 372,800
24-04-11 1.3 +4.84% 181,811
24-04-10 1.24 -3.88% 183,218

Delayed Quote Nasdaq, April 15, 2024 at 04:00 pm EDT

More quotes
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.29 USD
Average target price
5.4 USD
Spread / Average Target
+318.60%
Consensus